 Eli Lilly's diabetes drug, Manjaro, gained Chinese regulatory approval for weight loss today. Last month, Novo Nordisk's Ozempic received the same approval, fueling competition in a nation that's among the world's most severely hit by obesity. Erica Herskowitz, Bloomberg Radio. This is KRDO's Morning News on KRDO Newsradio. It's 6.30, the news now.